In The Literature
JAMA Oncol

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial

Eur J Cancer

Long-term Outcome of the REMAGUS 02 Trial, a Multicenter Randomised Phase II Trial in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy With or Without Celecoxib or Trastuzumab According to HER2 Status

BMJ Open

Efficacy and Safety of Lapatinib and Trastuzumab for HER2-Positive Breast Cancer: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

JAMA Oncol

Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study

BMC Cancer

Development of a Test that Measures Real-Time HER2 Signaling Function in Live Breast Cancer Cell Lines and Primary Cells

Ann Surg Oncol

Results of a Phase Ib Trial of Combination Immunotherapy With a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

Eur J Surg Oncol

Standardization of Oncoplastic Breast Conserving Surgery

Cancer Res

IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer

Breast Cancer Res

Phase II, Randomized, Placebo-Controlled Study of Dovitinib in Combination with Fulvestrant in Postmenopausal Patients with HR2-positive, HER2-negative Breast Cancer That Had Progressed During or After Prior Endocrine Therapy


Pathological Complete Response of HER2-Positive Breast Cancer to Trastuzumab and Chemotherapy Can Be Predicted by HSD17B4 Methylation

J Transl Med

Association of Osteopontin With Specific Prognostic Factors and Survival in Adjuvant Breast Cancer Trials of the Hellenic Cooperative Oncology Group

Ther Adv Med Oncol

Progress With Palbociclib in Breast Cancer: Latest Evidence and Clinical Considerations

Breast Cancer Res Treat

Clinical Tumor Stage is the Most Important Predictor of Pathological Complete Response Rate After Neoadjuvant Chemotherapy in Breast Cancer Patients

Breast Cancer Res Treat

Multicenter Analysis of Neoadjuvant Docetaxel, Carboplatin, and Trastuzumab (TCH) in Patients With HER2-Positive Breast Cancer

Clin Cancer Res

Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients With HER2-Positive Advanced Solid Tumors, with an Expansion Cohort in HER2-Positive Metastatic Breast Cancer (MBC)

Breast Cancer Res

18FDG-PET/CT for Predicting the Outcome in ER-Positive/HER2-Negative Breast Cancer Patients: Comparison of Clinicopathological Parameters and PET Image-Derived Indices Including Tumor Texture Analysis

Ann Oncol

Incidence and Management of Diarrhea in Patients With HER2-Positive Breast Cancer Treated With Pertuzumab

Breast Cancer

Complete Remission in Metastatic Breast Cancer: Expecting the Unexpected


pCR Rates in Patients With Bilateral Breast Cancer After Neoadjuvant Anthracycline-Taxane Based-Chemotherapy. A Retrospective Pooled Analysis of Individual Patient Data From Four German Neoadjuvant Trials

Drugs Real World Outcomes

HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes

N Engl J Med

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness

J Clin Oncol

Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities

Endcocr Rel Cancer

ErbB-2 Nuclear Function in Breast Cancer Growth, Metastasis and Resistance to Therapy


Prognostic Impact of Total and Tyrosine Phosphorylated GIV/Girdin in Breast Cancers


The Associations Between Mast Cell Infiltration, Clinical Features and Molecular Types of Invasive Breast Cancer

Practice Update

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

J Clin Oncol

Protein Intake and Breast Cancer Survival in the Nurses’ Health Study

BMC Cancer

Decreased Expression of Stomatin Predicts Poor Prognosis in HER2-Positive Breast Cancer

Oncology Letters

Trastuzumab as a Preoperative Monotherapy Does Not Inhibit HER2 Downstream Signaling in HER2-Positive Breast Cancer

Breast Cancer Research and Treatment

Inhibition of 6-Phosphofructo-2-kinase (PFKFB3) Suppresses Glucose Metabolism and the Growth of HER2+ Breast Cancer

Cancer Science

CITED2 in Breast Carcinoma as a Potent Prognostic Predictor Associated With Proliferation, Migration, and Chemoresistance


Loss of the Oncogenic Phosphatase PRL-3 Promotes a TNF-R1 Feedback Loop That Mediates Triple-Negative Breast Cancer


MicroRNA-224 Inhibits Proliferation and Migration of Breast Cancer Cells by Down-Regulating Fizzled 5 Expression

New England Journal of Medicine

Adaptive Randomization of Neratinib in Early Breast Cancer

Clinical Breast Cancer

Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer

BioMed Central Cancer

Prognostic Impact of AJCC Response Criteria for Neoadjuvant Chemotherapy in Stage II/III Breast Cancer Patients: Breast Cancer Subtype Analyses

JAMA Oncology

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis

European Journal of Cancer

HannaH Phase III Randomised Study: Association of Total Pathological Complete Response With Event-Free Survival in HER2-Positive Early Breast Cancer Treated With Neoadjuvant-Adjuvant Trastuzumab After 2 Years of Treatment-Free Follow-up

Journal of Clinical Oncology

Phase III Trial Evaluating Letrozole as First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

The Lancet Oncology

Neoadjuvant Nab-Paclitaxel in Breast Cancer: Trial Results and Patient Care

Pathology International

The Assessment of HER2 Status in Breast Cancer: The Past, the Present, and the Future

Breast Cancer Research and Treatment

Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 (HER2) Fluorescent In Situ Hybridization (FISH) Testing Increase HER2 Positive and HER2 Equivocal Breast Cancer Cases; Retrospective Study of HER2 FISH Results of 836 Invasive Breast Cancers

The Lancet Oncology

Pathological Complete Remission and Long-Term Outcome—What Do We Know in 2016?

New England Journal of Medicine

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Journal of Clinical Oncology

Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer

The Lancet Oncology

Neratinib Improves Invasive Disease–Free Survival in HER2-Positive Breast Cancer

The Oncologist

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer

Clinical Cancer Research

Relationship Between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Journal of Oncology Practice

Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary

The Lancet Oncology

Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients With HER2-Positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Journal of Clinical Oncology

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

The Lancet Oncology

Afatinib Plus Vinorelbine Versus Trastuzumab Plus Vinorelbine in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Had Progressed on One Previous Trastuzumab Treatment (LUX-Breast 1): An Open-Label, Randomised, Phase 3 Trial

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.